FDA Approval Alert: The Need-to-Know | Nogapendekin Alfa-inbakicept/BCG in BCG-unresponsive NMIBC

In April 2024, the FDA approved nogapendekin alfa-inbakicept plus Bacillus Calmette-Guérin (BCG) as a treatment for patients with BCG-unresponsive, non-muscle invasive bladder cancer (NMBIC) with carcinoma in-situ.

Nogapendekin alfa-inbakicept is now approved for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer.
FDA Approves Nogapendekin Alfa-inbakicept/BCG in BCG-unresponsive NMIBC
Article
Apr 22, 2024 10:37 PM
Nogapendekin alfa-inbakicept is now approved for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer.